Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

February 07, 2020

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

February 22, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

January 11, 2019

News Daily News

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

December 20, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

News Daily News

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.